Skip to main navigation Skip to search Skip to main content

Tilsotolimod Exploits the TLR9 Pathway to Promote Antigen Presentation and Type 1 IFN Signaling in Solid Tumors: A Multicenter International Phase I/II Trial (ILLUMINATE-101)

  • Hani Babiker
  • , Erkut Borazenci
  • , Vivek Subbiah
  • , Sanjiv Agarwala
  • , Alain Algazi
  • , Jacob Schachter
  • , Michael Lotem
  • , Corinne Maurice-Dror
  • , Daniel Hendler
  • , Shah Rahimian
  • , Hans Minderman
  • , Cara Haymaker
  • , Daruka Mahadevan
  • , Chantale Bernatchez
  • , Ravi Murthy
  • , Rolf Hultsch
  • , Nadia Kaplan
  • , Gregory Woodhead
  • , Charles Hennemeyer
  • , Srinivas Chunduru
    • Peter M. Anderson, Adi Diab, Igor Puzanov

Research output: Contribution to journal › Article › peer-review

10   Link opens in a new tab Scopus citations

Fingerprint

Dive into the research topics of 'Tilsotolimod Exploits the TLR9 Pathway to Promote Antigen Presentation and Type 1 IFN Signaling in Solid Tumors: A Multicenter International Phase I/II Trial (ILLUMINATE-101)'. Together they form a unique fingerprint.
Sort by

Immunology and Microbiology

Medicine and Dentistry